Have Kymera Therapeutics Insiders Been Selling Stock?
Some Kymera Therapeutics, Inc. (NASDAQ:KYMR) shareholders may be a little concerned to see that the Chief Legal Officer & Corporate Secretary, Brian Adams, recently sold a substantial US$744k worth of stock at a price of US$117 per share. That's a big disposal, and it decreased their holding size by 11%, which is notable but not too bad.
Kymera Therapeutics Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by the Chief Financial Officer, Bruce Jacobs, for US$1.1m worth of shares, at about US$89.66 per share. That means that even when the share price was below the current price of US$117, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 6.7% of Bruce Jacobs's holding.
In the last year Kymera Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
View our latest analysis for Kymera Therapeutics
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
Does Kymera Therapeutics Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Kymera Therapeutics insiders own 1.2% of the company, currently worth about US$118m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
So What Do The Kymera Therapeutics Insider Transactions Indicate?
An insider sold Kymera Therapeutics shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Kymera Therapeutics. Every company has risks, and we've spotted 4 warning signs for Kymera Therapeutics (of which 1 is a bit unpleasant!) you should know about.
But note: Kymera Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.